Immunocan launches alpaca-derived nanobody platform, ImmuAlpaca® Mouse, for therapeutic molecule construction.
Immunocan launches innovative alpaca-derived nanobody discovery platform, ImmuAlpaca® Mouse. In-situ replacement of IGH-VDJ genes in the mouse genome with alpaca IGH-VDJ genes marked significant progress. Nanobodies, derived from camelid heavy chain-only antibodies, offer increased stability due to substitutions in the FR2 region. With a 15 kDa molecular weight, these small antigen-binding fragments are flexible and easy to use in therapeutic molecule construction.
June 01, 2024
3 Articles